H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the 11 Best Stocks to Buy for Investment.

On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C. Wainwright remains positive on HALO, considering the strategic and financial strength of its ENHANZE platform. Kapoor believes the recent business developments with Takeda and Skye are a significant win for the company, expanding ENHANZE’s reach beyond oncology. The analyst expects these deals to help ENHANZE reach into large and durable markets such as inflammatory bowel disease and obesity.

H.C. Wainwright Sees Strength in Halozyme Therapeutics ENHANZE Platform, Reiterates Buy Rating

In other news, on January 8, Morgan Stanley slightly lowered the price target on HALO from $79 to 75, keeping an Overweight rating. The analyst at Morgan Stanley expects small-to-mid-cap U.S. biotech stocks to outperform in 2026 as commercial names shift from ‘capital consumers to producers.’ The analyst sees large-cap biopharma companies facing a looming patent cliff.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on the research, development, and commercialization of proprietary enzymes and devices worldwide.

While we acknowledge the potential of HALO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HALO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.

Disclosure: None. This article is originally published at Insider Monkey.